List of publications

1. List of Publications G.J.L.H. van Leenders
List of Publications (update March 1rst, 2012)
77) C. Schroten, N.F. Dits, E.W. Steyerberg, R. Kranse, G. van Leenders, C.H. Bangma, R. Kraaij: The
additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression. Cancer Immunol
Immunother 2011; Epub ahead of print. IF 4.3
76) G.J.L.H. van Leenders, R. Sookhlall, W.J. Teubel, C.M.A. de Ridder, S. Reneman, A. Sacchetti, C.J.
Vissers, W. van Weerden, G. Jenster: Activation of c-MET induces a stem-like phenotype in human prostate
cancer. PLOS One 2011; 6: e26753. IF 4.4
75) M.J. Roobol, H.A. van Vugt, S. Loeb, X. Zhu, M. Bul, C.H. Bangma, G. van Leenders, E.W. Steyerberg,
F.H. Schröder: Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in
the ERSPC risk calculators. Eur Urol 2012; 61: 577-583. IF 8.8
74) A.M. Hoogland, G. Jenster, W.M. van Weerden, J. Trapman, T. van der Kwast, M.J. Roobol, F.H.
Schröder, M.F. Wildhagen, G.J.L.H. van Leenders: ERG immunohistochemistry is not predictive for PSA
recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol
2011; Epub ahead of print. IF 4.2
73) B.W. van Rhijn, T.H. van der Kwast, S.S. Alkhateeb, N.E. Fleshner, G.J. van Leenders, P.J. Bostrom,
M.N. van der Aa, D.M. Kakiashvili, C.H. Bangma, M.A. Jewett, A.R. Zlotta: A new and highly prognostic
system to discern T1 bladder cancer substage. Eur Urol 2012; 61: 378-384. IF 8.8
72) M.A. Rijlaarsdam, H.A. van Herk, A.J. Gillis, H. Stoop, G. Jenster, J. Martens, G.J. van Leenders, W.
Dinjens, A.M. Hoogland, M. Timmermans, L.H. Looijenga: Specific detection of OCT3/4 isoform A/B/B1
expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell
tumours. Br J Cancer 2011; Epub ahead of print. IF 4.8
71) E.S. Martens-Uzunova, S.E. Jalava, N.F. Dits, G.J. van Leenders, S. Møller, J. Trapman, C.H. Bangma,
T. Litman, T. Visakorpi, G. Jenster: Diagnostic and prognostic signatures from the small non-coding RNA
transcriptome in prostate cancer. Oncogene 2012; 31: 978-991. IF 7.4
70) G. van Soest, E. Regar, T.P. Goderie, N. Gonzalo, S. Koljenović, G.J. van Leenders, P.W. Serruys, A.F.
van der Steen: Pitfalls in Plaque Characterization by OCT Image Artifacts in Native Coronary Arteries. JACC
Cardiovasc Imaging 2011; 4: 810-813. IF 5.5
69) B. Furusato, G.J. van Leenders, J. Trapman, T. Kimura, S. Egawa, H. Takahashi, M. Furusato, T.
Visakorpi, H. Hano: Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort:
diagnostic use in Japanese prostate cancer patients. Pathol Int 2011; 61: 409-414. IF 1.5
68) A Broeks, M.K. Schmidt, M.E. Sherman, F.J. Couch, J.L. Hopper, G.S. Dite, C. Apicella, L.D. Smith, F.
Hammet, M.C. Southey, L.J. van 't Veer, R. de Groot, V.T. Smit, P.A. Fasching, M.W. Beckmann, S. Jud,
A.B. Ekici, A. Hartmann, A. Hein, R. Schulz-Wendtland, B. Burwinkel, F. Marme, A. Schneeweiss, H.P. Sinn,
C. Sohn, S. Tchatchou, S.E. Bojesen, B.G. Nordestgaard, H. Flyger, D.D. Orsted, D. Kaur-Knudsen, R.L.
Milne, J.I. Pérez, P. Zamora, P.M. Rodríguez, J. Benítez, H. Brauch, C. Justenhoven, Y.D. Ko, U. Hamann,
H.P. Fischer, T. Brüning, B. Pesch, J. Chang-Claude, S. Wang-Gohrke, M. Bremer, J.H. Karstens, P.
Hillemanns, T. Dörk, H.A. Nevanlinna, T. Heikkinen, P. Heikkilä, C. Blomqvist, K. Aittomäk, K. Aaltonen, A.
Lindblom, S. Margolin, A. Mannerma, V.M. Kosma, J.M. Kauppinen, V. Kataja, P. Auvinen, M. Eskelinen, Y.
Soini, G. Chenevix-Trench, A.B. Spurdle, J. Beesley, X. Chen, H. Holland, D. Lambrechts, B. Claes, T.
Vandorpe, P. Neven, H. Wildiers, D. Flesch-Janys, R. Hein, T. Löning, M. Kosel, Z.S. Fredericksen, X.
Wang, G.G. Giles, L. Baglietto, G. Severi, C. McLean, C.A. Haiman, B.E. Henderson, L. Le Marchand, L.N.
Kolonel, G.G. Alnæs, V. Kristensen, A.L. Børresen-Dale, D.J. Hunter, S.E. Hankinson, I.L. Andrulis, A.M.
Mulligan, F.P. O'Malley, P. Devilee, P. Huijts, R.A. Tollenaar, C.J. van Asperen, C. Seynaeve, S.J. Chanock,
J. Lissowska, L. Brinton, B. Peplonska, J. Figueroa, X.R. Yang, M.J. Hooning, A. Hollestelle, R.A. Oldenburg,
A. Jager, M. Kriege, B. Ozturk, G.J. van Leenders, P. Hall, K. Czene, K. Humphreys, J. Liu, A. Cox, D.
Connley, H.E. Cramp S.S. Cross, S.P. Balasubramanian, M.W. Reed, A.M. Dunning, D.F. Easton, M.K.
Humphreys, C. Caldas, J. Lubinski, A. Jakubowska, T. Huzarski, T. Byrski, C. Cybulski, B. Gorski, J.
Gronwald, P. Brennan, S. Sangrajrang, V. Gaborieau, C.Y. Shen, C.N. Hsiung, J.C. Yu, S.T. Chen, G.C.
Hsu, M.F. Hou, C.S. Huang, H. Anton-Culver, A. Ziogas, P.D. Pharoah, M. Garcia-Closas. Low penetrance
breast cancer susceptibility foci are associated with specific breast tumor subtypes: findings from the Breast
Cancer Association Consortium. Hum Mol Genet 2011; 20: 3289-3303. IF 8.1
1

2. List of Publications G.J.L.H. van Leenders
67) T. Wolters, R. Montironi, R. Mazzucchelli, M. Scarpelli, M.J. Roobol, R.C. van den Bergh, P.J. van
Leeuwen, R.F. Hoedemaeker, G.J. van Leenders, F.H. Schröder, T.H. van der Kwast: Comparison of
incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy.
Prostate 2012; 72: 108-115. IF 3.4
66) G.J.L.H. van Leenders, J.L. Boormans, C.J. Vissers, A.M. Hoogland, A.A.J.W.M. Bressers, B. Furusato,
J. Trapman. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for
pathology practice. Mod Pathol 2011; 24: 1128-1138. IF 4.2
65) A.M. Hoogland, A. Dahlman, K.J. Vissers, T. Wolters, F.H. Schröder, M.J. Roobol, A.S. Bjartell, G.J.L.H.
van Leenders: CRISP-3 and β-MSP on prostate cancer needle-biopsies do not have predictive value for
subsequent prostatectomy outcome. BJU Int 2011; Epub ahead of print. IF 3.2
64) T. Wolters, M.J. Roobol, P.J. van Leeuwen, R.C.N. van den Bergh, R.F. Hoedemaeker, G.J.L.H. van
Leenders, F.H. Schröder, T.H. van der Kwast: A critical analysis of the tumor volume threshold for clinically
insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185: 121-125. IF
3.9
63) T.C. Zuiverloon, J.L. Boormans, J. Trapman, G.J.L.H. van Leenders, E.C. Zwarthoff: No evidence of
FGFR3 mutations in prostate cancer. Prostate 2010; 71: 637-641. IF 3.4
62) M.J. Roobol, F.H. Schroder, G.J. van Leenders, D. Hessels, R.C. van den Bergh, T. Wolters, P.J. van
Leeuwen: Performance of Prostate Cancer Antigen 3 (PCA3) and prostate-specific antigen in prescreened
men: reproducibility and detection characteristics for prostate cancer patients with PCA3 scores (≥100). Eur
Urol 2010; 58: 893-899. IF 8.8
61) B.W.G. van Rhijn, T.C. Zuiverloon, A.N. Vis, F. Radvanyi, G.J.L.H. van Leenders, B.C.M. Ooms, W.J.
Kirkels, G.A. Lockwood, E.R. Boevé, A.C. Jöbsis, E.C. Zwarthoff, T.H. van der Kwast: Molecular grade
(FGFR3/MIB-1) and EORTC risk-scores are predictive in primary non-muscle-invasive bladder cancer. Eur
Urol 2010; 58: 433-441. IF 8.8
60) M.J. Roobol, F.H. Schroder, P. van Leeuwen, T. Wolters, R.C. van den Bergh, G.J.L.H. van Leenders,
D. Hessels: Performance of the Prostate Cancer Antigen 3 (PCA3) gene and prostate-specific antigen in
prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010; 58: 475-481. IF
8.8
59) L. Bañez, L. Sun, G.J.L.H. van Leenders, T.M. Wheeler, C.H. Bangma, S.J. Freedland, M.M. Ittmann,
A.L. Lark, J.F. Madden, A. Hartman, G. Weiss, E. Castaños-Vélez: Clinical validation of PITX2 methylation
as a predictor of high risk PSA recurrence in post-radical prostatectomy prostate cancer patients. J Urol
2010; 184: 149-156. IF 3.9
58) J.L. Boormans, H. Korsten, A.C. Ziel-van der Made, G.J.L.H. van Leenders, P.C. Verhagen, J.
Trapman: E17K substitution in AKT1 in prostate cancer. Br J Cancer 2010; 102: 1491-1494. IF 4.8
57) T.P. Goderie, G. van Soest, H.M. Garcia-Garcia, N. Gonzalo, S. Koljenović, G.J.L.H. van Leenders, F.
Mastik, E. Regar, J.W. Oosterhuis, P.W. Serruys, A.F. van der Steen: Combined optical coherence
tomography and intravascular ultrasound radio frequency data analysis for plaque characterization.
Classification accuracy of human coronary plaques in vitro. Int J Cardiovasc Imaging 2010; 26: 843-850. IF
2.5
56) G. van Soest, T. Goderie, E. Regar, S. Koljenović, G.J.L.H. van Leenders, N. Gonzalo, S. van Noorden,
T. Okamura, B.E. Bouma, G.J. Tearney, J.W. Oosterhuis, P.W. Serruys, A.F. van der Steen: Atherosclerotic
tissue characterization in vivo by optical coherence tomography attenuation imaging. J Biomed Opt 2010; 15:
15: 011105 Epub ahead of print. IF 3.2
55) Th.H. van der Kwast, A. Evans, G. Lockwood, D. Tkachuk, K. Watson, D.G. Bostwick, J.I. Epstein, P.A.
Humphrey, R. Montironi, G.J.L.H. van Leenders, C-G. Pihl, I. Neetens, P. Martikainen, M. Laurila, C.
Mazerolles, L. Bubendorf, J. Srigley: Variability of diagnostic opinion among pathologists for single small
atypical foci in prostate biopsies. Am J Surg Path 2010; 34: 169-177. IF 5.2
2

3. List of Publications G.J.L.H. van Leenders
54) T. Wolters, M.J. Roobol, P.J. van Leeuwen, R.C. van den Bergh, R.F. Hoedemaeker, G.J.L.H. van
Leenders, F.H. Schröder, T.H. van der Kwast: Should Pathologists Routinely Report Prostate Tumour
Volume? The Prognostic Value of Tumour Volume in Prostate Cancer. Eur Urol 2010; 57: 821-829. IF 8.8
53) J.L. Boormans, K.G. Hermans, A.C. Made, G.J.L.H. van Leenders, M.F. Wildhagen, L. Collette, F.H.
Schröder, J. Trapman, P.C. Verhagen: Expression of the Androgen-Regulated Fusion Gene TMPRSS2-ERG
Does Not Predict Response to Endocrine Treatment in Hormone-Naïve, Node-Positive Prostate Cancer. Eur
Urol 2010; 57: 830-835. IF 8.8
52) B.W.G. van Rhijn, G.J.L.H. van Leenders, B.C.M. Ooms, W.J. Kirkels, A.L. Zlotta, E.R. Boevé, A.C.
Jöbsis, T.H. van der Kwast: The pathologist’s mean grade is constant and individualizes the prognostic value
of bladder cancer grading. Eur Urol 2010; 57: 1052-1057. IF 8.8
51) T. Wolters, C.J. Vissers, C.H. Bangma, F.H. Schröder, G.J.L.H. van Leenders: The value of EZH2,
p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low risk prostate cancer in selecting men with
significant prostate cancer at prostatectomy. BJU Int 2010; 106: 280-286. IF 3.2
50) J. Hofland, W.M. van Weerden, N.F.J. Dits, J. Steenbergen, G.J.L.H. van Leenders, G. Jenster, F.H.
Schröder, F.H. de Jong: Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Cancer Res 2010; 70: 1256-1264. IF 8.2
49) T. Wolters, Th.H. van der Kwast , C.J. Vissers, M. Roobol, F.H. Schröder, G.J.L.H. van Leenders:
False-negative prostate needle-biopsies during histological examination: identification, characterization and
clinical follow-up. Am J Surg Path 2010; 34: 35-43. IF 5.2
48) G. van Soest, T.P. Goderie, N. Gonzalo, S. Koljenović, G.J.L.H. van Leenders, E. Regar, P.W. Serruys,
A.F. van der Steen: Imaging atherosclerotic plaque composition with intracoronary optical coherence
tomography. Neth Heart J 2009; 17: 448-450. IF 1.4
47) K.G. Hermans, J.L. Boormans, D. Gasi, G.J.L.H. van Leenders, G. Jenster, P. Verhagen, J. Trapman:
Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable
prognosis of prostate cancer. Clin Cancer Res 2009; 15: 6398-6403. IF 7.3
46) R.R. Jurhill, J.H. van der Veen, G.J.L.H. van Leenders, P.C.M.S. Verhagen: Reduction of serum-PSA
levels following varicella zoster infection and valaciclovir treatment in local prostate cancer. Eur Urol 2009;
56: 392-394. IF 8.8
45) M.A. den Bakker, B. Beverloo, M. van Noesel, C. Meeuwis, G.J.L.H. van Leenders: Extra-axial NUT
translocation carcinoma ex-pleomorphic adenoma of the parotis gland. Am J Surg Path 2009; 33: 1253-
1258. IF 5.2
44) L. Egevad, F. Algaba, D.M. Berney, L. Boccon-Gibod, D.F. Griffiths, A. Lopez-Beltran, G. Mikuz, M.
Varma, R. Montironi, European Network of Uropathology: The European Network of Uropathology: a
novel mechanism for communication between pathologists Anal Quant Cytol Histol 2009; 31: 90-95. IF 0.6
43) F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan,
H. Lilja, M. Zappa, L.J. Denis, F. Recker, A. Berenguer, L. Määttänen, C.H. Bangma, G. Aus, A. Villers, X.
Rebillard, T. van der Kwast, B.G. Blijenberg, S.M. Moss, H.J. de Koning, A. Auvinen, ERSPC Investigators:
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-
1328. IF 53.5
42) L.M.G. Moons, F.H. Wolfhagen, R. Beukers, R.A. de Man, G.J.L.H. van Leenders, H.R. van Buuren: a
rare cause of large liver cysts. Am J Gastroenterology 2009; 104: 1056-1058. IF 6.9
41) J.G. van Roermund, D.E. Kok, M.F. Wildhagen, L.A. Kiemeney, F. Struik, S. Sloot, I.M. van Oort, C.A.
Hulsbergen-van de Kaa, G.J.L.H. van Leenders, C.H. Bangma, J.A. Witjes: Body mass index as a
prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. BJU Int 2009;
104: 321-324. IF 3.2
40) R.C. van den Bergh, T. Wolters, M.C. Spaander, F.H. Schröder, G.J.L.H. van Leenders: Non-prostatic
pathology on needle-biopsy - colorectal carcinoid: a case report: Cases J 2009; 2: 75. IF 0.6
3

4. List of Publications G.J.L.H. van Leenders
39) R.A. Alwani, S.J.C.M.M. Neggers, M. van der Klift, M.G.A. Baggen, G.J.L.H. van Leenders, M.O. van
Aken, W.W. de Herder, A.J. van der Lely, R.A. Feelders: Cushing’s syndrome due to ectopic ACTH
production by (neuroendocrine) prostate carcinoma. Pituitary 2009; 12: 280-283. IF 2.3
38) J.L. Boormans, K.G. Hermans, G.J.L.H. van Leenders, J. Trapman, P.C.M.S. Verhagen: An activating
mutation in AKT1 in human prostate cancer. Int J Cancer 2008; 123: 2725-2726. IF 4.9
37) A. Al-Mamgani, W.L.J. van Putten, W.D. Heemsbergen, G.J.L.H. van Leenders, A. Slot, M.F.H.
Dielwart, L. Incrocci, J.V. Lebesque: Update of the Dutch multicenter dose escalation trial of radiotherapy for
localized prostate cancer. Int J Rad Oncol Biol Phys 2008; 72: 980-988. IF 4.5
36) C-L Lai, R. van den Ham, G.J.L.H. van Leenders, J. van der Lugt, E. Teske: Histopathological and
immunohistochemical characterization of canine prostate cancer. Prostate 2008; 68: 477-488. IF 3.4
35) C-L Lai, R. van den Ham, G.J.L.H. van Leenders, J. van der Lugt, E. Teske: Comparative
characterization of the canine normal prostate in intact and castrated animals. Prostate 2008; 68: 498-507.
IF 3.4
34) J.L. Boormans, M.F. Wildhagen, C.H. Bangma, P.C.M.S. Verhagen, G.J.L.H. van Leenders: Histological
characterization of lymph node metastases in prostate cancer: correlation with cancer specific survival. BJU
Int 2008; 102: 1589-1593. IF 3.2
33) C. Gosselaar, M.J. Roobol, S. Roemeling, T. Wolters, G.J.L.H. van Leenders, F.H. Schröder: The value
of an additional hypoechoic lesion-directed biopsy core for the detection of prostate cancer. BJU Int 2008;
101: 685-690. IF 3.2
32) T. Wolters, M.J. Roobol, F.H. Schröder, T.H. van der Kwast, S. Roemeling, I.W. van der Cruijsen-Koeter,
C.H. Bangma, G.J.L.H. van Leenders: Can non-malignant biopsy features identify men at increased risk of
biopsy-detectable prostate cancer at re-screening after four years? (ERSPC Rotterdam section). BJU Int
2008; 101: 283-288. IF 3.2
31) M.T. Kummeling, B.W. de Jong, C. Laffeber, D.J. Kok, P.C. Verhagen, G.J.L.H. van Leenders, R.H. van
Schaik, C.S. van Woerden, A. Verhulst, C.F. Verkoelen: Tubular and interstitial nephrocalcinosis. J Urol
2007; 178: 1097-1103. IF 3.9
30) R. Postma, F.H. Schröder, G.J.L.H. van Leenders, R.F. Hoedemaeker, A.N. Vis, M.J. Roobol, T.H. van
der Kwast: Cancer detection and cancer characteristics in the European Randomized Study of Screening for
Prostate Cancer (ERSPC) – section Rotterdam: a comparison of two rounds of screening. Eur Urol 2007; 52:
89-97. IF 8.8
29) S. Roemeling, M.J. Roobol, S.H. de Vries, T. Wolters, C. Gosselaar, G.J.L.H. van Leenders, F.H.
Schröder: Active surveillance for prostate cancer detected in three subsequent rounds of a screening trial:
characteristics, PSA doubling times, and outcome. Eur Urol 2007; 51: 1244-1250. IF 8.8
28) G.J.L.H. van Leenders, D. Dukers, D. Hessels, S.W. van den Kieboom, C.A. Hulsbergen, J.A. Witjes,
A.P. Otte, C.J. Meijer, F.M. Raaphorst: Polycomb-group oncogenes EZH2, BMI1, and RING1 are
overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007; 52: 455-463.
IF 8.8
27) A.M. DeMarzo, E.A. Platz, J.I. Epstein, T. Ali, A. Billis, T.Y. Chan, L. Cheng, M. Datta, L. Egevad, D.
Ertoy-Baydar, X. Farre, S.W. Fine, K.A. Iczkowski, M. Ittmann, B.S. Knudsen, M. Loda, A. Lopez-Beltran, C.
Magi-Galluzzi, G. Mikuz, R. Montironi, E. Pikarsky, G. Pizov, M.A. Rubin, H. Samaratunga, T. Sebo, I.A.
Sesterhenn, R.B. Shah, S. Signoretti, J. Simko, G. Thomas, P. Troncoso, T.T. Tsuzuki, G.J.L.H. van
Leenders, X.J. Yang, M. Zhou, W.D. Figg, A. Hoque, M.S. Lucia: A working group classification of focal
prostate atrophy lesions. Am J Surg Pathol 30; 2006: 1281-1291. IF 5.2
26) R. Postma, G.J.L.H. van Leenders, M.J. Roobol, F.H. Schröder, T.H. van der Kwast: Tumour features in
the control and screening arm of a randomized trial of prostate cancer. Eur Urol 50; 2006: 70-75. IF 8.8
25) S. Roemeling, G.J.L.H. van Leenders, F.H. Schröder: Very late local recurrence after surgery for
prostate cancer unaccompanied by detectable PSA levels. Prostate Cancer Prostatic Dis 2006; 6: 192-194.
IF 2.3
4

5. List of Publications G.J.L.H. van Leenders
24) M.N. van der Aa, G.J.L.H. van Leenders, E.W. Steyerberg, B.W. van Rhijn, A.C. Jobsis, E.C. Zwarthoff,
T.H. van der Kwast: A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation.
Hum Pathol 2005; 36: 981-986. IF 3.0
23) T.H. van der Kwast, R. Postma, R.F. Hoedemaeker, G.J.L.H. van Leenders, F.H. Schröder: Features of
prostate cancers detected during a prevalence screening round. The Rotterdam experience. Can J Urol
2005; 12 (Suppl 3): 16-20. IF 0.8
22) F.A. van Dorsten, M. van der Graaf, M.R.W. Engelbrecht, G.J.L.H. van Leenders, A. Verhofstad, M.
Rijpkema, J.J.M.C.H. de la Rosette, J.O. Barentsz, A. Heerschap: Combined quantitative dynamic contrast-
enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging
2004; 20: 279-287. IF 2.7
21) J.A. Schalken, G.J.L.H. van Leenders: Cellular and molecular biology of the prostate epithelial stem
cell. Urology 2003; 62 (Suppl 1): 11-20. IF 2.3
20) M.R. Engelbrecht, H.J. Huisman, R.J. Laheij, G.J. Jager, G.J.L.H. van Leenders, C.A. Hulsbergen-van
de Kaa, J.J. de la Rosette, J.G. Blickman, J.O. Barentsz: Discrimination of prostate cancer from normal
peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003;
29: 248-254. IF 6.1
19) G.J.L.H. van Leenders, J.A. Schalken: Epithelial cell differentiation in the human prostate epithelium:
implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol 2003; 46 (Suppl):
3-10. IF 4.7
18) D. Hessels, J.M. Klein Gunnewiek, I. van Oort, H.F. Karthaus, G.J.L.H. van Leenders, B. van Balken,
L.A. Kiemeney, J.A. Witjes, J.A. Schalken: DD3(PCA3)-based molecular urine analysis for the diagnosis of
prostate cancer. Eur Urol 2003; 44: 8-15. IF 8.8
17) G.J.L.H. van Leenders, W.R. Gage, J.L. Hicks, B. van Balken, T.W. Aalders, J.A. Schalken, A.M. De
Marzo: Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.
Am J Pathol 2003; 162: 1529-1537. IF 5.2
16) T.E. Goosens, J.J. de la Rosette, C.A. Hulsbergen-van de Kaa, G.J.L.H. van Leenders, H. Wijkstra: The
value of dynamic contrast enhanced power Doppler ultrasound imaging in the localization of prostate cancer.
Eur Urol 2003; 43: 124-131. IF 8.8
15) J.P. Sedelaar, G.J.L.H. van Leenders, T.E. Goosens, C.A. Hulsbergen-van de Kaa, N.P. van Adrichem,
H. Wijkstra, J.J. de la Rosette: Value of contrast ultrasonography in the detection of significant prostate
cancer: correlation with radical prostatectomy specimens. Prostate 2002; 52: 246-253. IF 3.4
14) G.J.L.H. van Leenders, B. van Balken, T.A. Aalders, C.A. Hulsbergen-van de Kaa, D.J. Ruiter, J.A.
Schalken: Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for
prostate cancer invasion. Prostate 2002; 51: 98-107. IF 3.4
13) J.P. Sedelaar, J.G. van Roermund, G.J.L.H. van Leenders, C.A. Hulsbergen-van de Kaa, H. Wijkstra,
J.J.M.C.H. de la Rosette: Three-dimensional grayscale ultrasound: evaluation of prostate cancer compared
with benign prostatic hyperplasia. Urology 2001; 57: 914-920. IF 2.3
12) G.J.L.H. van Leenders, J.A. Schalken: Stem cell differentiation within the human prostate epithelium:
implications for prostate carcinogenesis. BJU Int 2001; 88 (Suppl 2): 35-42. IF 3.2
11) G.J.L.H. van Leenders, T.W. Aalders, C.A. Hulsbergen-van de Kaa, D.J. Ruiter, J.A. Schalken:
Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001; 195:
563-570. IF 7.3
10) J.P. Sedelaar, G.J.L.H. van Leenders, C.A. Hulsbergen-van de Kaa, H.G. van der Poel, J.A. van der
Laak, F.M.J. Debruyne, H. Wijkstra, J.J.M.C.H. de la Rosette: Microvessel density: correlation between
contrast ultrasonography and histology of prostate cancer. Eur Urol 2001; 40: 285-293. IF 8.8
9) K. Tomita, A. van Bokhoven, G.J.L.H. van Leenders, T.E.G. Ruijter, C.F.J. Jansen, M.J.G. Bussemakers,
J.A. Schalken: Cadherin switching in human prostate cancer progression. Cancer Res 2000; 60: 3650-3654.
IF 8.2
5

6. List of Publications G.J.L.H. van Leenders
8) G.J.L.H. van Leenders, H.B.P.M. Dijkman, C.A. Hulsbergen-van de Kaa, D.J. Ruiter, J.A. Schalken:
Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using
triple-staining confocal scanning microscopy. Lab Invest 2000; 80: 1251-1258. IF 4.4
7) D. Unal, J.P.M. Sedelaar, R.G. Aarnink, G.J.L.H. van Leenders, H. Wijkstra, F.M.J. Debruyne, J.J.M.C.H.
de la Rosette: Three-dimensional contrast-enhanced power Doppler ultrasonography and conventional
examination methods: the value of diagnostic predictors of prostate cancer. BJU Int 2000; 86: 58-64. IF 3.2
6) T.E.G. Ruijter, G.J.L.H. van Leenders, G.J. Miller, F.M.J. Debruyne, C.A. Hulsebergen-van de Kaa:
Errors in histological grading by prostatic needle biopsy specimens: frequency and predisposing factors. J
Pathol 2000; 192: 229-233. IF 7.3
5) G.J.L.H. van Leenders, H.P. Beerlage, T.E.G. Ruijter, J.J.M.C.H. de la Rosette, C.A. van de Kaa:
Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised
adenocarcinoma of the prostate. J Clin Pathol 53; 2000: 391-394. IF 2.5
4) J.P.M. Sedelaar, R.G. Aarnink, G.J.L.H. van Leenders, H.P. Beerlage, F.M.J. Debruyne, H. Wijkstra,
J.J.M.C.H. de la Rosette: The application of three-dimensional contrast-enhanced ultrasound to measure
volume of affected tissue after HIFU treatment for localized prostate cancer. Eur Urol 2000; 37: 559-568. IF
8.8
3) H.P. Beerlage, G.J.L.H. van Leenders, G.O.N. Oosterhof, J.A. Witjes, T.E.G. Ruijter, C.A. Hulsbergen-
van de Kaa, F.M.J. Debruyne, J.J.M.C.H. de la Rosette: High Intensity Focused Ultrasound (HIFU) followed
after one to two weeks by radical retropubic prostatectomy; results of a prospective study. Prostate 1999; 39:
41-46. IF 3.4
2) M.G. Steffens, O.C. Boerman, W.J.G. Oyen, P.H.M. Kniest, J.A. Witjes, G.O.N. Oosterhof, G.J.L.H. van
Leenders, F.M.J. Debruyne, F.H.M. Corstens, E. Oosterwijk. Intratumoural distribution of two consecutive
injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose
radioimmunotherapy. Cancer Res 1999; 59: 1615-1619. IF 8.2
1) H.G. van der Poel, D. Hessels, G.J.L.H. van Leenders, M.J.G. Bussemakers, J.A. Schalken, J. A. Witjes,
F.M.J. Debruyne: Multifocal transitional cell cancer and p53 mutation analysis. J Urol 1998; 160: 124-125. IF
3.9
Editorial comments
4) Eur Urol 2008; 54: 1323
3) Dutch J Urol 2008
2) Eur Urol 2007; 52: 125
1) Eur Urol 2006; 50:1031
6